Validation of NCM460 cell model as control in antitumor strategies targeting colon adenocarcinoma metabolic reprogramming: Trichostatin A as a case study

Biochimica et Biophysica Acta - General Subjects

Volumn 1840, Issue 6, 2014, Pages 1634-1639

  Alcarraz Vizán, Gema ^a,c   Sánchez Tena, Susana ^a   Moyer, Mary Pat ^b   Cascante, Marta ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

^b INCELL Corporation ^*  (United States)

^c INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

Author keywords

Colon cancer; Glycolysis; Metabolic adaptation; Metabolic profile; Trichostatin A; Tumour metabolism

Indexed keywords

LACTIC ACID; PENTOSE PHOSPHATE; TRICHOSTATIN A; GLYCOLYTIC ENZYME;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CARBON METABOLISM; CELL DIFFERENTIATION; CELL PROLIFERATION; CITRIC ACID CYCLE; COLON ADENOCARCINOMA; CONTROLLED STUDY; ENZYME SYNTHESIS; GLUCOSE INTAKE; GLYCOLYSIS; HUMAN; HUMAN CELL; MASS FRAGMENTOGRAPHY; NUCLEAR REPROGRAMMING; PENTOSE PHOSPHATE CYCLE; PRIORITY JOURNAL; ADENOCARCINOMA CELL LINE; AGED; HT 29 CELL LINE; MALE; METABOLIC FLUX ANALYSIS; METABOLIC REPROGRAMMING; NCM460 CELL LINE; NERVE CELL DIFFERENTIATION; PHENOTYPE;

COLON CANCER; GLYCOLYSIS; METABOLIC ADAPTATION; METABOLIC PROFILE; TRICHOSTATIN-A; TUMOUR METABOLISM;

ADENOCARCINOMA; ANTINEOPLASTIC AGENTS; CITRIC ACID CYCLE; COLONIC NEOPLASMS; GLUCOSE; GLYCOLYSIS; HISTONE DEACETYLASE INHIBITORS; HT29 CELLS; HUMANS; HYDROXAMIC ACIDS; LACTIC ACID; PENTOSE PHOSPHATE PATHWAY;

EID: 84897903774     PISSN: 03044165     EISSN: 18728006     Source Type: Journal    
DOI: 10.1016/j.bbagen.2013.12.024     Document Type: Article

References (25)

1. O. Warburg, On the origin of cancer cells, Science (New York, N.Y.) 123 (1956) 309-314.
2. C. Munoz-Pinedo, N. El Mjiyad, J.E. Ricci, Cancer metabolism: current perspectives and future directions, Cell Death Dis. 3 (2012) e248.
3. A. Schulze, A.L. Harris, How cancer metabolism is tuned for proliferation and vulnerable to disruption, Nature 491 (2012) 364-373.
4. S. Sanchez-Tena, G. Alcarraz-Vizan, S. Marin, J.L. Torres, M. Cascante, Epicatechin gallate impairs colon cancer cell metabolic productivity, J. Agric. Food Chem. 61 (2013) 4310-4317.
5. E. Im, J. Jung, S.H. Rhee, Toll-like receptor 5 engagement induces interleukin-17C expression in intestinal epithelial cells, J. Interferon Cytokine Res. 32 (2012) 583-591.
6. B.R. You, W.H. Park, Trichostatin A induces apoptotic cell death of HeLa cells in a Bcl-2 and oxidative stress-dependent manner, Int. J. Oncol. 42 (2013) 359-366.
7. M.P. Moyer, L.A. Manzano, R.L. Merriman, J.S. Stauffer, L.R. Tanzer, NCM460, a normal human colon mucosal epithelial cell line, In Vitro Cell. Dev. Biol. 32 (1996) 315-317.
8. G. Alcarraz-Vizan, J. Boren, W.N. Lee, M. Cascante, Histone deacetylase inhibition results in a common metabolic pro file associated with HT29 differentiation, Metabolomics 6 (2010) 229-237.
9. W.N. Lee, L.G. Boros, J. Puigjaner, S. Bassilian, S. Lim, M. Cascante, Mass isotopomer study of the nonoxidative pathways of the pentose cycle with [1,2-13C2]glucose, Am. J. Physiol. 274 (1998) E843-E851.
10. J. Boren, W.N. Lee, S. Bassilian, J.J. Centelles, S. Lim, S. Ahmed, L.G. Boros, M. Cascante, The stable isotope-based dynamic metabolic profile of butyrate-induced HT29 cell differentiation, J. Biol. Chem. 278 (2003) 28395-28402. (Pubitemid 36935740)
11. J.M. Lee, E.P. Gianchandani, J.A. Papin, Flux balance analysis in the era of metabolomics, Brief. Bioinform. 7 (2006) 140-150. (Pubitemid 44404880)
12. P. Vizan, L.G. Boros, A. Figueras, G. Capella, R. Mangues, S. Bassilian, S. Lim, W.N. Lee, M. Cascante, K-ras codon-specific mutations produce distinctive metabolic phenotypes in NIH3T3 mice [corrected] fibroblasts, Cancer Res. 65 (2005) 5512-5515. (Pubitemid 40911149)
13. C.V. Dang, MYC on the path to cancer, Cell 149 (2012) 22-35.
14. J.P. Bayley, P. Devilee, The Warburg effect in 2012, Curr. Opin. Oncol. 24 (2012) 62-67.
15. L.G. Boros, P.W.N. Lee, J.L. Brandes, M. Cascante, P. Muscarella, W.J. Schirmer, W.S. Melvin, E.C. Ellison, Nonoxidative pentose phosphate pathways and their direct role in ribose synthesis in tumors: is cancer a disease of cellular glucose metabolism? Med. Hypotheses 50 (1998) 55-59. (Pubitemid 28046401)
16. A. Ramos-Montoya, W.N. Lee, S. Bassilian, S. Lim, R.V. Trebukhina, M.V. Kazhyna, C.J. Ciudad, V. Noe, J.J. Centelles, M. Cascante, Pentose phosphate cycle oxidative and nonoxidative balance: a new vulnerable target for overcoming drug resistance in cancer, Int. J. Cancer 119 (2006) 2733-2741. (Pubitemid 44846223)
17. M. Zanuy, A. Ramos-Montoya, O. Villacanas, N. Canela, A. Miranda, E. Aguilar, N. Agell, O. Bachs, J. Rubio-Martinez, M.D. Pujol, W.N. Lee, S. Marin, M. Cascante, Cyclin-dependent kinases 4 and 6 control tumor progression and direct glucose oxidation in the pentose cycle, Metabolomics 8 (2012) 454-464.
18. H.F. Duncan, A.J. Smith, G.J. Fleming, P.R. Cooper, Histone deacetylase inhibitors induced differentiation and accelerated mineralization of pulp-derived cells, J. Endod. 38 (2012) 339-345.
19. X. Hu, X. Zhang, L. Dai, J. Zhu, Z. Jia, W. Wang, C. Zhou, Y. Ao, Histone deacetylase inhibitor trichostatin A promotes the osteogenic differentiation of rat adipose-derived stem cells by altering the epigenetic modifications on runx2 promoter in a BMP signaling-dependent manner, Stem Cells Dev. 22 (2013) 248-255.
20. P. Vizan, G. Alcarraz-Vizan, S. Diaz-Moralli, O.N. Solovjeva, W.M. Frederiks, M. Cascante, Modulation of pentose phosphate pathway during cell cycle progression in human colon adenocarcinoma cell line HT29, Int. J. Cancer 124 (2009) 2789-2796.
21. H.S. Kwon, B. Huang, N. Ho Jeoung, P. Wu, C.N. Steussy, R.A. Harris, Retinoic acids and trichostatin A (TSA), a histone deacetylase inhibitor, induce human pyruvate dehydrogenase kinase 4 (PDK4) gene expression, Biochim. Biophys. Acta 1759 (2006) 141-151. (Pubitemid 43816112)
22. A. Grabarska, M. Dmoszynska-Graniczka, E. Nowosadzka, A. Stepulak, Histone deacetylase inhibitors - molecular mechanisms of actions and clinical applications, Postepy Hig. Med. Dosw. (Online) 67 (2013) 722-735.
23. S.P. Perrine, O. Hermine, T. Small, F. Suarez, R. O'Reilly, F. Boulad, J. Fingeroth, M. Askin, A. Levy, S.J. Mentzer, M. Di Nicola, A.M. Gianni, C. Klein, S. Horwitz, D.V. Faller, A phase 1/2 trial of arginine butyrate and ganciclovir in patients with Epstein-Barr virus-associated lymphoid malignancies, Blood 109 (2007) 2571-2578. (Pubitemid 46425904)
24. B.W. Shi, W.F. Xu, The development and potential clinical utility of biomarkers for HDAC inhibitors, Drug Discov. Ther. 7 (2013) 129-136.
25. A. Villar-Garea, M. Esteller, Histone deacetylase inhibitors: understanding a new wave of anticancer agents, Int. J. Cancer 112 (2004) 171-178. (Pubitemid 39244355)